Birgitta Leuthner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Birgitta Leuthner has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Andree Blaukat
Translational Innovation Platform Oncology and Immuno-Oncology, The Healthcare Business of Merck KGaA, Darmstadt, Germany
88 shared publications - Amy Hin Yan Tong
Donnelly Centre, University of Toronto, Toronto, Canada
63 shared publications - Beatrix Blume
Discovery Technologies, Merck Healthcare KGaA, the healthcare business of Merck KGaA, Darmstadt, Germany
63 shared publications - Diane Hahn
Research Unit Oncology, Merck Healthcare KGaA, the healthcare business of Merck KGaA, Darmstadt, Germany
63 shared publications - Dirk Wienke
The healthcare business of Merck KGaA, Darmstadt, Germany
63 shared publications - Felix Rohdich
Discovery Technologies, Merck Healthcare KGaA, the healthcare business of Merck KGaA, Darmstadt, Germany
63 shared publications
Latest Publications
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Discovery of M4205, a potent inhibitor of disease-relevant KIT-mutant variants. A, Schematic overview of clinically observed mutations in different domains of the RTK KIT and estimated target coverage (green: positive; red: negative) of approved and investigational KIT inhibitors. 1L, first-line; 2L, second-line; 3L, third-line; 4L, fourth-line. B, X-ray structures of M4205 (2.1 Å resolution; PDB ID: 7ZW8) in complex with the kinase domain of wild-type KIT. For clarity, only interacting residues are shown including H-bonds and Van der Waals contacts (depicted as dashed black and brown lines, respectively). C, Potent biochemical inhibition of clinically relevant KIT mutations in exon 11, exon 13/14, and exon 17 is demonstrated for M4205 compared with approved KIT inhibitors imatinib, sunitinib, and ripretinib. IC50 values show mean with SD of two technical replicates. D, Cellular target engagement of KIT-mutant forms with M4205 is confirmed in NanoBRET assays. Target coverage is determined by competitive displacement of the NanoBRET tracer with 1, 10, or 100 nmol/L M4205 and is shown as mean with SD of two technical replicates.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Discovery of M4205, a potent inhibitor of disease-relevant KIT-mutant variants. A, Schematic overview of clinically observed mutations in different domains of the RTK KIT and estimated target coverage (green: positive; red: negative) of approved and investigational KIT inhibitors. 1L, first-line; 2L, second-line; 3L, third-line; 4L, fourth-line. B, X-ray structures of M4205 (2.1 Å resolution; PDB ID: 7ZW8) in complex with the kinase domain of wild-type KIT. For clarity, only interacting residues are shown including H-bonds and Van der Waals contacts (depicted as dashed black and brown lines, respectively). C, Potent biochemical inhibition of clinically relevant KIT mutations in exon 11, exon 13/14, and exon 17 is demonstrated for M4205 compared with approved KIT inhibitors imatinib, sunitinib, and ripretinib. IC50 values show mean with SD of two technical replicates. D, Cellular target engagement of KIT-mutant forms with M4205 is confirmed in NanoBRET assays. Target coverage is determined by competitive displacement of the NanoBRET tracer with 1, 10, or 100 nmol/L M4205 and is shown as mean with SD of two technical replicates.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Dose- and exposure-dependent inhibition of KIT autophosphorylation with M4205 in the GIST430/654 model. A, Tumor-bearing mice were treated daily with three different doses of M4205 for 5 days, and inhibition of KIT autophosphorylation compared with untreated controls was determined at different time points after last treatment. B, Free plasma concentrations of M4205 were plotted against the effect of KIT inhibition which revealed an in vivo IC50 of 4 nmol/L. C–E, Inhibition of KIT autophosphorylation is correlated with free plasma concentration over time for the three dosage groups (dashed line: 4 nmol/L free in vivo IC50; dotted line: 16 nmol/L free cellular IC50).
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Dose- and exposure-dependent inhibition of KIT autophosphorylation with M4205 in the GIST430/654 model. A, Tumor-bearing mice were treated daily with three different doses of M4205 for 5 days, and inhibition of KIT autophosphorylation compared with untreated controls was determined at different time points after last treatment. B, Free plasma concentrations of M4205 were plotted against the effect of KIT inhibition which revealed an in vivo IC50 of 4 nmol/L. C–E, Inhibition of KIT autophosphorylation is correlated with free plasma concentration over time for the three dosage groups (dashed line: 4 nmol/L free in vivo IC50; dotted line: 16 nmol/L free cellular IC50).
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Mouse PK and human dose prediction
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Mouse PK and human dose prediction
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Biochemical inhibition of KIT variants
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Biochemical inhibition of KIT variants
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Split of M4205 concentration and FLT3 inhibition
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Split of M4205 concentration and FLT3 inhibition
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
In vivo antitumor activity of M4205 in xenograft models expressing oncogenic KIT mutations. Tumor bearing mice were treated daily with M4205 by oral gavage at doses indicated (10 mice per group). Body weight of mice was measured daily, and tumor growth was followed twice weekly. A, Exon 11–mutant GIST CDX model GIST430 (del560-576). B, Exon 11–mutant GIST PDX model (GS11342 and WKV557fs). C, Exon 11–mutant (del560-576) and exon 13–mutant (V654A) GIST CDX model GIST430/654. D, Exon 11–mutant (WK557del) and exon 13–mutant (V654A) GIST PDX model GS11331. E, Exon 11–mutant (WK557del) and exon 17–mutant (Y823D) GIST PDX model GS5108. F, Exon 17–mutant (N822K) AML CDX model Kasumi-1. Different letters within the graph indicate statistical significance (P < 0.05) according to two-way ANOVA analysis on log-transformed data. G, Treatment effects (%) for these different studies were plotted as T/C ratios. According to preclinical RECIST criteria, T/C ratios between 73% and −66% indicate tumor stasis and T/C ratios below −66% indicate tumor regression.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
In vivo antitumor activity of M4205 in xenograft models expressing oncogenic KIT mutations. Tumor bearing mice were treated daily with M4205 by oral gavage at doses indicated (10 mice per group). Body weight of mice was measured daily, and tumor growth was followed twice weekly. A, Exon 11–mutant GIST CDX model GIST430 (del560-576). B, Exon 11–mutant GIST PDX model (GS11342 and WKV557fs). C, Exon 11–mutant (del560-576) and exon 13–mutant (V654A) GIST CDX model GIST430/654. D, Exon 11–mutant (WK557del) and exon 13–mutant (V654A) GIST PDX model GS11331. E, Exon 11–mutant (WK557del) and exon 17–mutant (Y823D) GIST PDX model GS5108. F, Exon 17–mutant (N822K) AML CDX model Kasumi-1. Different letters within the graph indicate statistical significance (P < 0.05) according to two-way ANOVA analysis on log-transformed data. G, Treatment effects (%) for these different studies were plotted as T/C ratios. According to preclinical RECIST criteria, T/C ratios between 73% and −66% indicate tumor stasis and T/C ratios below −66% indicate tumor regression.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Cellular P-ERK1/2 and P-AKT inhibition
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Cellular P-ERK1/2 and P-AKT inhibition
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
In vivo formulation and administration
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
In vivo formulation and administration
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
In vivo P-KIT and P-ERK1/2 inhibition
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
In vivo P-KIT and P-ERK1/2 inhibition